Prostate Cancer Diagnostics Market Report by Type, Test Type, End User, Regions, and Company Analysis 2024-2032

Global Prostate Cancer Diagnostics Market size is predicted to be almost US$ 11.89 Billion by 2032. The CAGR for the prostate cancer diagnostics market from 2024 to 2032 is 12.35%. The publisher stated that it valued US$ 4.17 Billion in 2023.

Abnormal cell growth that takes over the body's regular cell function and causes difficulties for the body to function normally is what leads to cancer. Although prostate cancer is a frequent illness in men, it is very curable when caught early. The prostate gland, which is located between the penis and the bladder, is where it all starts. Although the exact cause is unknown to experts, the danger rises with age. When cancer cells are restricted to the prostate or even slightly outside of it (extra-prostatic extension), they remain "localized" and do not spread to other areas of the body. Prostate cancer is described as "advanced" if it spreads to other bodily parts. Early-stage prostate cancer typically exhibits no symptoms. Prostate cancer risk factors include age and race, among other factors. Many tests are available to screen for prostate cancer. A digital rectal exam, a PSA blood test, scans, and a biopsy are a few examples of these.

• It is most likely in elderly men to get prostate cancer. According to Cancer Research UK, males 75 years of age and above account for 35 out of 100 (35%) new cases per year on average.
• With the exception of skin cancer, prostate cancer is the most frequent malignancy among males. An estimated 288,300 males in the US will receive a prostate cancer diagnosis in 2023. According to Cancer.Net, 1,414,259 persons worldwide were expected to receive a prostate cancer diagnosis in 2020.
• It also stated that prostate cancer claimed the lives of an estimated 375,304 persons globally.

Global Prostate Cancer Diagnostics Market Trends

• Prostate cancer diagnostics market growth is anticipated to be primarily driven by the growing worldwide elderly population and technical improvements in the cancer diagnostics area during the forecast period.
• The United Nations Population Division projects that over the next three decades, the number of people 65 and older will double, reaching 1.6 billion by 2050.
• For instance - Prostate cancer is more common in men who have specific genetic features that they inherited from their mother. Lynch syndrome and hereditary BRCA gene mutations are two examples of these characteristics. There are no established rules about whether, when, or how to screen men who have a high hereditary risk of prostate cancer. In order to find out more about the frequency and early stage of these malignancies, researchers at the National Cancer Institute (NCI) are employing magnetic resonance imaging (MRI) of the prostate in men who are at high risk. It is also being tested if routine scans on these guys can identify tumors early on, before they metastasis, or spread to other parts of the body.
• Moreover, NCI researchers are investigating if PSMA-PET imaging can also identify men who are at high risk of their cancer reoccurring as part of the Cancer MoonshotTM. In the future, this kind of imaging might be able to assist in predicting which patients require more intensive post-diagnosis care, such radiation therapy in addition to surgery.
• The ability to customize diagnostic techniques based on unique patient features is presented by the worldwide prostate cancer diagnostics industry's growing emphasis on personalized medicine.
• For instance - Prostate Cancer UK provided funding for a study that categorized the variations in prostate cancer cases across men and found a subset of men with gene alterations related to a procedure known as DNA damage repair. Olaparib, the first precision medication for prostate cancer, was created as a result of this. Tests on men with prostate cancer revealed that olaparib, a very effective medication for women with ovarian and breast cancer, can prolong life by several months in men with DNA damage repair mutations.

Asia-Pacific Prostate Cancer Diagnostics Market

• The rising incidence and awareness of prostate cancer in Asia-Pacific is likely to drive significant growth in the prostate cancer diagnostics market.
• In India, 64% of men with prostate cancer survive for five years. One of the top 10 most common cancers in India is prostate cancer. Men 65 years of age and older are typically affected. On the other hand, younger men living in metropolitan areas and falling within the 35-44 and 55-64 age groups have been more frequently reported to have cancer recently.
• "Know Your Risks" is the topic for Prostate Cancer Awareness Month in 2023 at Pace Hospitals in Hyderabad, India. The topic emphasizes the value of routine examinations, disseminating knowledge about risk factors and symptoms, and offering assistance to individuals impacted by prostate cancer.
• The Asia-Pacific prostate cancer diagnostics market is anticipated to grow as a result of increased government and private sector investments in the healthcare industry as well as rising demand for cutting-edge medical care.
• In August 2023 - Japan has approved the use of AstraZeneca and MSD's Lynparza (olaparib) in conjunction with prednisolone and abiraterone for the treatment of adult patients with castration-resistant prostate cancer that includes distant metastases (mCRPC) due to a BRCA mutation. The sixth most common cause of cancer-related deaths in the region and the most common cancer among men in Japan is prostate cancer.

Global Prostate Cancer Diagnostics Industry News

F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Hologic Inc., Qiagen N.V., and OPKO Health Inc. are the leading businesses in the global prostate cancer diagnostics market.

• In May 2024 - In order to advance the development of AI algorithms for prostate cancer imaging, Siemens Healthineers and Blue Earth Diagnostics have struck a collaboration to share clinical data. Particularly, Blue Earth will make available de-identified clinical data from its Phase 3 Lighthouse study, which used the PET imaging agent Posluma (flotufolastat F 18). Siemens, for its part, intends to use the information to guide the creation of algorithms for the measurement and interpretation of prostate cancer images throughout its PET/CT imaging software.
• In September 2023 - MDxHealth SA and the University of Oxford worked together. The partnership seeks to investigate the relationship between the Genomic Prostate Score (GPS) test and the advancement of prostate cancer following localized prostate cancer treatment.
• In July 2023 - Blue Earth Diagnostics announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer now include the injection of POSLUMA (Flotufolastat F 18).
• In August 2023 - The FDA in the United States has authorized FoundationOneCDx to function as a supplemental diagnostic for Janssen's AKEEGA, which consists of niraparib and an abiraterone acetate Dual Action Tablet. Patients with metastatic castration-resistant prostate cancer that is BRCA-positive are the only ones eligible for this approval.
• In July 2023 - In association with Envision Sciences, Quest Diagnostics has announced the introduction of a new prostate cancer biomarker test via its subspecialty pathology company, AmeriPath.

Type - Market breakup in 4 viewpoints:

1. Benign Prostatic Hyperplasia
2. Prostatic Adenocarcinoma
3. Small Cell Carcinoma
4. Others

Test Type - Market breakup in 2 viewpoints:

1. Preliminary Tests
2. Confirmatory Tests

End User - Market breakup in 4 viewpoints:

1. Hospitals
2. Diagnostic Centers
3. Research Institutes
4. Others

Country - Market breakup in 25 viewpoints:

1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 United Arab Emirates
5.3 South Africa

All the Key players have been covered from 4 Viewpoints:

• Overview
• Recent Development
• Product Portfolio & Product Launch in Last 1 Year
• Revenue

Company Analysis:

1. F. Hoffman-La Roche AG
2. Bayer AG
3. Thermo Fisher Scientific Inc.
4. Abbott Laboratories Inc.
5. Siemens Healthineers AG
6. Becton Dickinson and Company
7. Agilent Technologies Inc.
8. Hologic Inc
9. Qiagen N.V.
10. OPKO Health Inc.